Treatment of Staphylococcus aureus endocarditis using moxifloxacin

被引:10
作者
Berrington, AW [1 ]
Koerner, RJ
Perry, JD
Bain, HH
Gould, FK
机构
[1] Freeman Rd Hosp, Dept Med Microbiol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England
[2] Freeman Rd Hosp, Dept Paediat, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England
关键词
moxifloxacin; endocarditis; quinolone; Staphylococcus aureus; therapy;
D O I
10.1078/1438-4221-00126
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The conventional treatment of staphylococcal endocarditis requires in-patient administration, is inconvenient, and is potentially toxic. Increasing experience with well-absorbed, well-tolerated and highly active agents such as the new quinolones has prompted interest in their use as therapeutic alternatives for the treatment of such infections. We describe a case of staphylococcal endocarditis which failed to respond to conventional therapy, but where the addition of moxifloxacin, an 8-methoxyquinolone, was curative.
引用
收藏
页码:237 / 239
页数:3
相关论文
共 10 条
[1]   MEDICAL-TREATMENT OF INFECTIVE ENDOCARDITIS - GENERAL-PRINCIPLES [J].
BESNIER, JM ;
CHOUTET, P .
EUROPEAN HEART JOURNAL, 1995, 16 :72-74
[2]  
DWORKIN RJ, 1989, LANCET, V2, P1071
[3]   Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains [J].
Jones, ME ;
Visser, MR ;
Klootwijk, M ;
Heisig, P ;
Verhoef, J ;
Schmitz, FJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :421-423
[4]   CIPROFLOXACIN AND RIFAMPIN, ALONE AND IN COMBINATION, FOR THERAPY OF EXPERIMENTAL STAPHYLOCOCCUS-AUREUS ENDOCARDITIS [J].
KAATZ, GW ;
SEO, SM ;
BARRIERE, SL ;
ALBRECHT, LM ;
RYBAK, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (08) :1184-1187
[5]   Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and streptococci of Lancefield Groups A and G [J].
MacGowan, AP ;
Bowker, KE ;
Wootton, M ;
Holt, HA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (06) :761-766
[6]   Penetration of moxifloxacin into peripheral compartments in humans [J].
Müller, M ;
Stass, H ;
Brunner, M ;
Möller, JG ;
Lackner, E ;
Eichler, HG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) :2345-2349
[7]  
Simmons NA, 1998, HEART, V79, P207
[8]   Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci [J].
von Eiff, C ;
Peters, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (04) :569-573
[9]   ANTIBIOTIC-TREATMENT OF ADULTS WITH INFECTIVE ENDOCARDITIS DUE TO STREPTOCOCCI, ENTEROCOCCI, STAPHYLOCOCCI, AND HACEK MICROORGANISMS [J].
WILSON, WR ;
KARCHMER, AW ;
DAJANI, AS ;
TAUBERT, KA ;
BAYER, A ;
KAYE, D ;
BISNO, AL ;
FERRIERI, P ;
SHULMAN, ST ;
DURACK, DT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (21) :1706-1713
[10]   Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration [J].
Wise, R ;
Andrews, JM ;
Marshall, G ;
Hartman, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) :1508-1510